Document is current
Any future updates will be listed below
-
Authors
Henkle, E. https://orcid.org/0000-0002-5190-9383
Dieckmann, N. F.
Franklin, H.
Cella, D.
Megson, G.
Daley, C. L.
Flume, P. A.
McShane, P. J.
Winthrop, K. L.
Quittner, A. L.
-
Funding
Funding for this research was provided by:
U.S. Food and Drug Administration (75F40121C00120)
- License Information
-
More Information
Article History
Received: 18 July 2025
Accepted: 9 March 2026
First Online: 3 May 2026
Declarations
:
: EH received consulting and/or advisory board fees for Spero, AN2, MannKind, and Evidera. PAF received consulting and grant funding from AN2, Insmed, Paratek and consulting from MicuRX, PJM received grant funding from Insmed, Paratek, AN2, KLW and CLD received consulting and grant funding from Insmed, Paratek, AN2. All other authors have no relevant financial or non-financial interests to declare.
: The study was approved centrally by BRANY (IRB #21-08-566).
